Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Certara Inc (700)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.17 0.00    0.00%
29/07 - Delayed Data. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US15687V1098 
S/N:  A2QJL8
  • Volume: 0
  • Bid/Ask: 9.14 / 9.51
  • Day's Range: 9.17 - 9.17
Certara 9.17 0.00 0.00%

Certara Inc Company Profile

 
Get an in-depth profile of Certara Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustrySoftware & IT Services
SectorTechnology
Employees

1517

Equity Type

ORD

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Contact Information

Address 4 Radnor Corporate Center Suite 350
Radnor, 19087
United States
Phone 415 237 8272
Fax -

Top Executives

Name Age Since Title
Malcolm Rowland - - Chair of Simcyp Scientific Advisory Board
Donald E. Mager - - Member of Simcyp Scientific Advisory Board
Yuichi Sugiyama - - Member of Simcyp Scientific Advisory Board
J Brian Houston - - Member of Simcyp Scientific Advisory Board
Geoff Tucker - - Member of Simcyp Scientific Advisory Board
Lawrence J. Lesko - 2015 Member of Simcyp Scientific Advisory Board
Stephen M. McLean - 2013 Independent Director
Jennifer B. Dressman - 2017 Member of Simcyp Scientific Advisory Board
Noriko Okudaira - 2019 Senior Consultant & Member of Simcyp Scientific Advisor Board
William F. Feehery 54 2019 CEO & Director
Matthew M. Walsh 58 2020 Independent Director
James E. Cashman 71 2018 Independent Chairman of the Board
Nancy Killefer 72 2021 Independent Director
Cynthia L. Collins 67 2021 Independent Director
David Spaight 65 2022 Independent Director
Eran Broshy 65 2022 Independent Director
Rosemary A. Crane 65 2022 Independent Director
John V. W. Reynders - 2024 Independent Director
Frederic Yves Bois - 2019 Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CERT Comments

Write your thoughts about Certara Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email